Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anifrolumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms MUSE
  • Sponsors MedImmune

    • Most Recent Events

    • 04 Jun 2022 Results of a pooled analysis assessing hypersensitivity profile of anifrolumab and need for pretreatment from following clinical studies: MUSE, TULIP-1, and TULIP-2 presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 17 May 2022 Results assessing he degree of concordance between BICLA and SRI(4) across anifrolumab trials ( TULIP-1, TULIP-2 and MUSE ) published in the Annals of the Rheumatic Diseases.
    • 16 Feb 2022 According to an AstraZeneca media release, Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top